This inventor holds 1 USPTO granted patent and 5 published patent applications. Top assignee: Genmab A+s. Active years: 2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2025
Title: Grietje Andringa: Innovator in Antibody Development
Introduction
Grietje Andringa is a prominent inventor based in Utrecht, Netherlands. She has made significant contributions to the field of biotechnology, particularly in the development of multispecific antibodies. Her work focuses on therapeutic applications, especially in cancer treatment.
Latest Patents
Grietje Andringa holds a patent for "Antibodies binding to fibroblast activation protein alpha and death receptor 4." This invention relates to a multispecific antibody that includes a FAPα binding region and a DR4 binding region. The patent outlines the pharmaceutical compositions that comprise these antibodies and their use in therapeutic and diagnostic procedures, particularly in cancer therapy. She has 1 patent to her name.
Career Highlights
Grietje is associated with Genmab AS, a leading biotechnology company known for its innovative cancer therapies. Her role at Genmab has allowed her to contribute to groundbreaking research and development in the field of immunotherapy.
Collaborations
Grietje has collaborated with notable colleagues, including Bart Ecg De Goeij and Ilse Jongerius. These partnerships have enhanced her research efforts and contributed to the advancement of antibody therapies.
Conclusion
Grietje Andringa is a key figure in the development of innovative antibody therapies, with a focus on cancer treatment. Her contributions to biotechnology continue to impact the field significantly.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile